2020
Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015
Wilson LE, Greiner MA, Altomare I, Rotter J, Dinan MA. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015. Journal Of Geriatric Oncology 2020, 12: 375-380. PMID: 33250425, DOI: 10.1016/j.jgo.2020.11.007.Peer-Reviewed Original ResearchConceptsProstate cancerCancer costsLung cancerBreast cancerProportion of patientsSystemic anticancer therapyPart D enrollmentNew malignanciesPatients 65Systemic therapyMedicare 5Colorectal cancerInvasive lungMedicare patientsCohort analysisMedicare populationMedicare beneficiariesPatientsSolid tumorsTherapyCancerAnticancer therapyCancer therapyFinancial burdenLung
2018
Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.
Wilson L, Greiner M, Altomare I, Rotter J, Dinan M. Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015. Journal Of Clinical Oncology 2018, 36: 23-23. DOI: 10.1200/jco.2018.36.30_suppl.23.Peer-Reviewed Original ResearchTargeted anti-cancer drugsCancer spendingCancer patientsD patientsBC patientsAnti-cancer drugsColorectal cancer populationPatients age 65Breast cancer patientsLung cancer patientsMedicare spendingElderly lungsElderly patientsPatient ageCC patientsLC patientsMedicare 5Colorectal cancerInvasive lungPatient populationCancer populationMedicare patientsNationwide utilizationRetrospective analysisMean cost